Green Cross Corp. has decided to stop US and European Phase III clinical trials with GreenGene F (beroctocog alfa) for hemophilia A and instead focus on developing the recombinant coagulation Factor VIII product in China after encountering delays in recruiting patients in the US.
The leading South Korean biopharma firm had originally expected the US clinical trial to take two to three years, but...